Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.161NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.58NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.75NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.411NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.217NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.35NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.17 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.41NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.527NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.18NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.500NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.147NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.487NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.68NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.121NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AA.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AS.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.115NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.127.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.88NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.423NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.550NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.261NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.3.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EP.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.15.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XCBNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.15.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CM.8.1.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XSNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.4.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.29NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.38NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.40NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.160.25NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.74NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.2.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.6.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.238NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.11NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.68NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.26NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BR.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.25NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.51NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FT.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.11.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used